BioNTech SE

BioNTech’s co‑founders exit sparks a leadership vacuum and new mRNA‑focused spin‑off, weighing on stock price while the oncology pipeline pushes future growth.

BioNTech’s founders plan to leave and launch a new mRNA firm, yet shares stay near $90 and analysts keep buy ratings—what this means for investors.

BioNTech’s 2025 earnings fall short, posting a sharp operating loss, but a robust cash reserve and a future‑focused pipeline aim to revive growth amid co‑founder exit.

BioNTech’s 2025 earnings and a patent lawsuit vs. Moderna create a volatile mix, pushing the biotech stock below key support and sparking short‑selling interest.

BioNTech’s pivot to oncology, a high‑profile lawsuit against Moderna and new leadership reshuffle signal a bold but risky strategy shift—investors weigh potential growth against looming legal and financial uncertainty.

BioNTech sues Moderna in Delaware over mRNA patent, sparking a new legal battle amid vaccine efficacy gains and a growing oncology pipeline.

BioNTech’s shift from COVID‑19 vaccines to a robust oncology pipeline, highlighted by its glioblastoma Phase‑2 trial and 2026 earnings, offers investors a look at the company’s future growth potential.

BioNTech’s FDA oncology approval and new CPO boost its shift from vaccines to cancer care, signaling stronger revenue prospects and market confidence.

BioNTech’s new Stanford study shows mRNA safety, easing regulatory scrutiny, yet the stock lags as investors weigh oncology pipeline and BMS partnership.

BioNTech’s latest oncology trial results—Pumitamig and Gotistobart—offer new hope amid mRNA regulatory headwinds, showing promise in breast and lung cancer while the stock lingers near a 52‑week low.